| Title |
Cost-Effectiveness of the 21-Gene Breast Cancer Assay in Mexico
|
|---|---|
| Published in |
Advances in Therapy, March 2015
|
| DOI | 10.1007/s12325-015-0190-8 |
| Pubmed ID | |
| Authors |
Juan Enrique Bargalló-Rocha, Fernando Lara-Medina, Victor Pérez-Sánchez, Rafael Vázquez-Romo, Cynthia Villarreal-Garza, Hector Martínez-Said, Robin J. Shaw-Dulin, Alejandro Mohar-Betancourt, Barnaby Hunt, Juliette Plun-Favreau, William J. Valentine |
| Abstract |
The 21-gene breast cancer assay (Oncotype DX(®); Genomic Health, Inc.) is a validated diagnostic test that predicts the likelihood of adjuvant chemotherapy benefit and 10-year risk of distant recurrence in patients with hormone-receptor-positive, human epidermal growth receptor 2-negative, early-stage breast cancer. The aim of this analysis was to evaluate the cost-effectiveness of using the assay to inform adjuvant chemotherapy decisions in Mexico. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Mexico | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 67 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 14% |
| Student > Master | 8 | 12% |
| Student > Bachelor | 8 | 12% |
| Student > Ph. D. Student | 7 | 10% |
| Student > Doctoral Student | 6 | 9% |
| Other | 17 | 25% |
| Unknown | 13 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 33% |
| Nursing and Health Professions | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Agricultural and Biological Sciences | 4 | 6% |
| Other | 14 | 20% |
| Unknown | 14 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 March 2015.
All research outputs
#14,443,165
of 23,592,647 outputs
Outputs from Advances in Therapy
#1,087
of 2,413 outputs
Outputs of similar age
#132,732
of 258,621 outputs
Outputs of similar age from Advances in Therapy
#14
of 24 outputs
Altmetric has tracked 23,592,647 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,413 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 258,621 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.